Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2019-04-01 Capital/Financing Update
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) under a Registration Statement on Form S-3. It discusses the offering and sale of shares of common stock, updates to the maximum amount of shares eligible for sale, and references the Distribution Agreement with a sales agent. The document is a supplement to a prospectus and relates to capital raising activities. It is not a financial report, earnings release, or management discussion. The content clearly fits the category of a Capital/Financing Update, as it provides details on securities offerings and related terms.
2019-04-01 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 1, 2019, by Leap Therapeutics, Inc. It provides an update on the company's product development and announces financial results for the year ended December 31, 2018. The document states that the full text of the press release is furnished as an exhibit (Exhibit 99.1) to this Form 8-K. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length of the document is 4108 characters, which is relatively short and consistent with an announcement rather than a full report. According to the "Menu vs Meal" rule, this is an announcement of financial results, not the full earnings release itself. Therefore, the document should be classified as an Earnings Release (ER) because it announces quarterly/periodical financial results, but since it is a Form 8-K with a press release attached, it is best classified as an Earnings Release (ER) with high confidence.
2019-04-01 English
10-K
Annual Report FY 2018
2019-04-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions "Item 8.01 Other Events" and references a press release about a presentation at a conference. There are no financial statements, detailed financial data, or comprehensive reports included. The document is short (3617 characters) and primarily serves as an announcement of an event and a press release filing. It does not fit into categories like Annual Report, Earnings Release, or Interim Report. It is not a certification or officer attestation. Given the nature of the filing and its content, the best classification is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like 8-Ks that do not fit other categories.
2019-03-18 English
SC 13D
Major Shareholding Notification
2019-02-15 English
SC 13G/A
Major Shareholding Notification
2019-02-14 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.